Medical Device Launch Plan: Clearance to Month Twelve

Bottom line: A medical device launch plan is built backward from the clearance date, not

forward from the calendar. Before the authorization, the buildable work is the site, the messaging,

and the sales tools, while claims about the device wait. At launch, four things have to be live: a

site that states the authorized indication correctly, reviewed sales collateral, one demand channel

you can actually staff, and a way to tell whether it worked. Companies that launch on five channels at

once usually cannot tell which one produced the pipeline, and they cut the wrong one.

This is a primer, not legal or regulatory advice. Section 2 describes what companies commonly do before an authorization exists, which is not the same thing as permission. Run every pre-authorization communication through your own regulatory affairs and legal teams.

This guide is written for the person who has to produce the plan. It assumes you have a submission in, or a clearance date you are working toward, and you need to know what happens in which month and who owns it. It is a sequence, not a template document. If what you need is the annual planning document itself, with the situation analysis, the SWOT, and the section-by-section structure, that is a different artifact and it lives at the medical device marketing plan template. If you want the narrative overview of Module 5 before the dated sequence, start at the medical device product launch guide.

Anchor Everything to the Clearance Date

The single structural decision in a device launch plan is what the dates are measured from, and most plans get it wrong on the first page by writing calendar months.

Write every date as an offset from the authorization, not as a date. A plan that says "email sequence live in March" dies the moment the submission moves. A plan that says "email sequence live at authorization plus 30 days" survives, because the whole sequence re-dates itself from one input. This sounds like a formatting preference. It is the difference between a plan you revise once and a plan you rebuild every quarter.

Two dates get conflated constantly and they are not the same. The authorization date is when FDA clears, approves, or grants. The first commercial shipment date is when you can actually put the device in a customer's hands, and it depends on manufacturing, inventory, labeling release, distributor readiness, and in some cases a trained field team. Marketing runs off the second one. Launching demand generation against a device that cannot ship for eleven weeks produces a pipeline of qualified people who go cold waiting.

Those stage positions are a planning frame, not a benchmark. They are not observed averages across device companies and this guide does not present them as such. Your dates come out of your own submission, your own manufacturing readiness, and your own buyer chain.

What to do when the date slips, and it will

Split the plan into two lists on the day you write it, because they behave completely differently when the date moves.

Elastic commitments are anchored to your authorization and re-date themselves for free: the website launch, the email sequence, the first paid campaign, sales training, the press moment, the collateral release. Moving these costs a calendar edit.

Fixed commitments are anchored to somebody else's calendar and do not move at all: exhibit space contracts and their payment schedules, conference abstract and speaker deadlines, print production runs, publication lead times, distributor and GPO contracting windows, and any signed agreement with a date in it. Moving these costs money, a forfeited deposit, or a full year of waiting for the next show cycle.

The rule that falls out of the split is short. Do not sign a fixed commitment against an elastic date unless you can afford to eat it. The most expensive version of this mistake in medtech is booking booth space at a major congress on the assumption that clearance lands before the show, and then exhibiting with a device you cannot promote yet. That is a real scenario with real rules attached and it is covered in the conference guide: FDA conference compliance.

When a slip happens, re-date the elastic list in one pass, then look at the fixed list and decide each item explicitly: eat it, renegotiate it, or repurpose it. What goes wrong is not the slip. It is a fixed commitment that nobody re-examined because the plan only had one list.

The Pre-Clearance Window

This is the section with real regulatory weight, and it is the one place in this guide where a wrong assumption is a compliance problem rather than a planning error. Everything below describes what device companies commonly have in flight before an authorization exists. It is a description of common practice, not a grant of permission, and the answer for your device depends on your pathway, your device's status, and your regulatory lead's judgment.

The rule underneath all of it

What you say about a device is evidence of what the device is for. Under 21 CFR 801.4, a device's intended use is established by the objective intent of the people who market it, and FDA looks at the circumstances surrounding distribution to determine that intent, including labeling, advertising, and oral or written statements by the firm or its representatives. So a claim made before an authorization exists is not a marketing decision that becomes real later. It is evidence now, and it can describe an intended use the agency has not evaluated.

For an investigational device the rule is explicit. 21 CFR 812.7 prohibits promoting or test marketing an investigational device before FDA has approved it for commercial distribution, limits charging to cost recovery rather than prohibiting charging outright, prohibits unduly prolonging an investigation, and prohibits representing that the device is safe or effective for the purposes being investigated. Investigational labeling under 21 CFR 812.5 has to carry a CAUTION statement identifying the device as investigational and limited by Federal law to investigational use, and it cannot represent the device as safe or effective for the purposes being investigated.

One scoping point matters more than it looks, because it decides which of the two paragraphs above applies to you. Part 812 governs devices that are the subject of a clinical investigation. A device that is simply awaiting a decision on a submission is not automatically in that category, so the two situations are analyzed differently and the difference is worth settling with your regulatory lead before anyone writes a line of pre-authorization copy. What applies in both situations is 801.4, because 801.4 is not about the device's paperwork status. It is about what your statements say the device is for.

Work that is usually in flight before the authorization

None of this depends on the authorization language, so waiting for clearance to start it is the most common way to lose three months at the front of a launch.

• Buyer research: who decides, who influences, who signs, and what evidence each of them responds to
• Positioning and the message architecture, which is the parent document every later piece of copy inherits from
• The corporate website: who the company is, the technology platform, the team, the pipeline in the general terms a company describes itself in
• The claims matrix: every claim you intend to make, in one column, and its intended source document in the other, built empty and filled in as evidence lands
• The review chain: who reviews what, in what order, and who signs, written down before there is anything to review
• Sales tool structure: the deck skeleton, the objection map, the demo path, the training outline, all of it built to take final claim language later
• Distribution, KOL, and investigator relationships, which run on their own timelines, are usually the longest lead item in the whole plan, and carry compliance and reporting obligations from the first meeting rather than from the first payment
• Measurement plumbing: analytics, CRM stages, lead definitions, and the attribution path, because retrofitting these after launch means the first six months of data are unusable

Work that usually waits for the authorization

• Any claim about the device's clinical performance, safety, or effectiveness
• Product pages that state an indication, since the indication does not exist in final form yet
• Availability, ordering, and pricing communications
• Sales outreach on the specific device, including reps describing it in the field, because 801.4 reaches oral statements by representatives
• Comparative claims of any kind
• The press moment, which is worth holding rather than splitting into a weak pre-announcement

The practical test that sorts most items is this: would this work have to be redone if the indication came back narrower than you expect? Work that survives a narrower indication can usually start now. Work that would have to be rebuilt should wait for the authorization's own language.

Three pre-clearance questions this guide will not answer for you

Each of these comes up in almost every launch plan, each one is genuinely fact-specific, and none of them should be decided from a guide. What follows is what the question turns on and who owns it, which is more useful than an answer that would not survive contact with your device.

Coming-soon pages, waitlists, and pre-registration forms. This is the most requested pre-authorization asset in medtech and there is no FDA guidance addressed to it, so anyone who quotes you a rule is quoting a practice rather than a citation. The analysis turns on a short list of inputs: whether the page communicates about the company or about the device, whether it makes any representation about performance or availability, whether it names an indication, and, for a device under investigation, whether collecting interest is promotion or test marketing within the meaning of 812.7. The answer genuinely can differ between an investigational device and a device awaiting a decision on a submission, which is the scoping point above. Whatever the page ends up saying becomes evidence of intended use under 801.4, so this is a regulatory sign-off before it is a design brief.

Conference presence before an authorization exists. Exhibiting, presenting data, and having the device physically present are three different activities with three different analyses, and a launch plan usually has to commit to the booth eight to twelve months before it knows the answer. Two constraints run in parallel and the second one is the one teams forget. The regulatory analysis belongs to your regulatory lead, and it is not the same analysis as the show-week rules for an authorized device that the conference guide covers. The organizer's own exhibitor rules are a separate, contractual constraint that frequently bites first, and they are knowable today: read the exhibitor agreement for what it says about unapproved and investigational products before the space is contracted, not after. See FDA conference compliance for the authorized-device case.

Investor and recruiting communications that describe the device. The honest answer is that this belongs to legal and investor relations, and marketing's job is to know that it exists rather than to write it. The one fact worth carrying into a marketing meeting is that 801.4 reaches statements by the firm and its representatives without regard to which department issued them or what the audience was called, so a sentence drafted for a product page does not become a different kind of sentence when it is pasted into a fundraising deck. Route it, and make sure the review chain in your plan has a lane for it.

The labeling item that quietly sets your launch date

Anything that meets the definition of labeling is a controlled document rather than a marketing asset, and it moves at the speed of change control rather than at the speed of a design review.

Under the Quality Management System Regulation, which took effect on February 2, 2026, design and development requirements sit at 21 CFR 820.10(c), which requires manufacturers of class II, class III, and certain listed class I devices to comply with ISO 13485:2016 Clause 7.3, and FDA's device labeling and packaging controls provision sits at 820.45. The former 21 CFR 820.30 design controls section is reserved under the QMSR, so any launch SOP or review checklist that still cites 820.30 as its regulatory basis is out of date and should be corrected before it is used to run a launch. Background is at the QMSR transition.

The planning consequence is the part marketers miss. If your launch collateral includes anything that is labeling, its release date is governed by a controlled process with its own review and approval steps, and marketing cannot compress it by working a weekend. Determine which launch assets are labeling and which are advertising before you build the launch calendar, not after. The determination, the review chain, and the substantiation table behind it are the subject of the sibling guide: medical device promotional review.

The designation is not the authorization

Launch plans lean on Breakthrough Device designation harder than any other document, because it is frequently the only third-party validation a company has before an authorization exists. Two facts should govern how a plan uses it. A designation is not a marketing authorization, and FDA's Breakthrough Devices Program guidance, final in September 2023, states that the eligibility considerations for the program are different from and do not change the statutory requirements for a marketing authorization. And FDA has published nothing on the promotional use of the designation, so a launch plan that builds a campaign on it is building on ground the agency has not addressed rather than on ground it has cleared.

The practical consequence for the plan is narrow. Keep any reference to a designation factual, dated, and tied to the designated indication, treat it as a statement about the program rather than as evidence about the device, and put it through the same review chain as every other claim. The treatment of designation language sits in medical device promotional review.

Pathway-specific launch language is its own subject and this guide links to it rather than restating it: De Novo and PMA launch marketing. The verbs are the part that gets published wrong. FDA clears a 510(k), grants a De Novo, and approves a PMA, and none of the three is interchangeable in a launch announcement.

One more boundary, stated once. Authorization in one market is not authorization in another. A device cleared in the United States may not be authorized elsewhere, and launch collateral that travels to a distributor in another market can carry claims that are not supportable there. Market gating and market-by-market website structure are their own subject and are not covered here.

Launch Month: The Minimum Viable Set

The most useful thing a launch plan can do in month zero is be shorter than the team wants it to be. Four things have to be live. Most launches over-build three of them and skip the fourth.

Define the launch metric before you launch

Pick the one number the launch is judged on, agree it with sales in writing, and agree what it is not. A launch judged on traffic produces traffic. A launch judged on qualified conversations produces a smaller number that means something. The number matters less than the fact that it was chosen before the data existed, because a metric chosen afterward is always the metric that makes the quarter look best.

Agree the lead definition with sales in the same conversation. Marketing and sales disagreeing about what counts as qualified is the single most common reason a working channel gets cut at month five, and it is entirely preventable with one meeting held before launch instead of after.

The internal launch usually gates revenue more than the external one

Marketing launches on a date. Sales becomes able to sell somewhere between two weeks and two quarters later, depending on whether the field was trained, whether the demo path exists, whether objection handling was written, and whether the collateral cleared review. If the field is not ready, demand generation is producing conversations that nobody can close, which reads in the data as a channel failure and is not one.

Put field readiness on the launch checklist as a gate, not as a parallel workstream. The related mechanics are at medical device launch email sequence and marketing automation workflows for a launch.

Months 1 to 6: Prove One Channel

The first half of year one has one job: find out whether a single demand channel produces qualified conversations repeatably. Not whether it produces traffic, and not whether it produces leads. Conversations, with people who can buy.

Pick the channel by where the buyer already is

Choose on evidence, not on preference. Three questions usually settle it. Is your buyer actively searching for a solution to this problem, or do they not know the category exists yet? Is the buying unit an individual clinician or a committee? And can you name the accounts, or is the market too large to list?

Active search with a nameable buyer points at search and content. An unaware market points at outbound, field, and education. A named and finite account list points at account-based work, and that one is usually better held for the second half of the year, once early demand data has told you which accounts to name.

What proving actually means

A channel is proven when three things are true at once, and all three are required.

• Volume is high enough that the result is not one lucky quarter, which you decide in advance rather than after seeing the number
• The path from first touch to qualified conversation is repeatable, meaning you can describe the steps and they happen again
• Somebody can state what a marginal dollar into that channel produces, even roughly, without opening a spreadsheet

If you cannot say all three by the decision date you set, the honest conclusion is usually that the channel was not staffed rather than that it does not work. Those two failures look identical in a dashboard and have opposite fixes.

Add the second channel only when the first has a repeatable path

The pressure to add channels arrives around month three, from a board deck. The argument against it is not purity, it is attribution: a second channel added before the first is understood makes both uninterpretable, and the decision that follows is a guess dressed as data.

There is one exception worth naming. Adding a channel that supports the proven one, retargeting behind organic search, or email behind a content channel, is not a second channel and does not create the attribution problem. Adding a channel that competes for the same budget and the same attention does.

Set the review date for the whole first half at the start, not at the end. Six months is long enough to learn something and short enough that a wrong call is recoverable.

Months 6 to 12: Conferences and Named Accounts

The second half of year one adds the two workstreams that need a proven base underneath them, and one of the two has a timing inversion that catches almost every first-time launch.

The conference decision happens early even though the show happens late

Exhibit space, sponsorship tiers, abstract submissions, speaking slots, and the good booth locations are contracted six to twelve months ahead. So the conference presence that lands in month ten is decided in month two or three, while you are still proving your first channel and have the least information you will ever have.

That is a genuine tension and there is no clean way out of it, but there is a way to make it cheaper. Decide the shortlist early because you have to, and stage the commitment: contract the space at the smallest defensible footprint, hold the sponsorship and build decisions as long as the show will let you, and know each deadline's actual date rather than assuming it is later than it is. Then let the first half of the year's data decide how much show you build, not whether you go.

For choosing the shows, choosing the right conference and the medical conference finder do the selection work. The full program is at the medical conference exhibitor guide, and show-week promotional rules are at FDA conference compliance.

Named-account work needs a list the first half produces

Account-based work is expensive per account and it is only worth it when the list is right. The argument for holding it until the second half is that months one through six generate the exact input the list needs: which accounts engaged, which titles opened, which objections repeated, and which conversations reached a committee. A target list built in month one is a guess. A target list built in month seven is an observation.

The workstream that is not marketing and will decide your revenue anyway

Coverage, coding, and payment pathways sit outside marketing and frequently determine whether a cleared device generates revenue in year one. Marketing does not own this, but a launch plan that does not name an owner for it is a launch plan with a hole in the middle. Name the owner, put the milestone dates in the same plan, and know which of your marketing commitments depend on it.

This guide does not name the pathways, and that is deliberate rather than lazy. The coverage landscape for new devices has moved more than once in the last two years, so a pathway list printed in an evergreen marketing guide would be a liability inside a year. Your market access lead has the current map.

There is one boundary a marketer does need, because it decides who writes the material. Statements about how a procedure is coded, covered, or paid are not ordinary marketing claims, because a provider may bill in reliance on them. Federal law treats health care economic information directed at payors, formulary committees, and similar entities as its own category under section 502(a) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 352(a), with its own conditions, and a company whose coding or billing direction a provider relies on can face exposure under the False Claims Act at 31 U.S.C. 3729(a)(1) for causing the submission of a false claim. The workable rule for a launch plan is that this material is produced by reimbursement or market access, reviewed the way a regulatory document is reviewed, and never drafted by marketing because a deadline is close.

Who Owns Each Stage

Every stage in this plan fails the same way: it belongs to everyone, so it belongs to no one. One named person per stage, and the name goes in the plan document.

On what this costs

This guide does not publish stage-by-stage cost figures, because Buzzbox Media does not have verified figures to publish for them and an invented range is worse than no range. Two places on this site do carry real numbers. The marketing budget calculator models a stage-appropriate budget from your own inputs, and the medtech marketing budget benchmark is Buzzbox Media's own benchmark work. Use those rather than a number from a launch template.

If your company is small enough that these roles collapse into one or two people, which is the normal case below fifty million in revenue, the table is still worth filling in. It stops being an org chart and becomes a list of the hats one person is wearing, which is exactly the argument for which hat to hand to somebody else. Team structure at different company sizes is at medical device marketing team structure.

The Launch Readiness Checklist

Run this against a real plan. Each line is either satisfied or it is not, and a launch with unsatisfied lines in sections A through D is not ready regardless of the date on the calendar.

A. The plan itself

• Every date in the plan is written as an offset from the authorization, not as a calendar date
• The authorization date and the first commercial shipment date are tracked as two separate dates
• Fixed commitments are listed separately from elastic ones, with the cost of moving each one written next to it
• One named owner is assigned to every stage, and every name is a person rather than a team
• The launch metric is chosen and written down, and what it is not measuring is written down beside it
• The lead definition is agreed with sales in writing, before launch

B. Regulatory and claims

• The claims matrix exists, with every intended claim and its source document
• The current authorized indication text is pulled from the authorization document, not from an internal summary
• Every launch asset has been determined to be labeling or advertising, and the determination is recorded
• Assets that are labeling have entered change control, with their release dates reflected in the launch calendar
• The review chain is written down, with one named approver who is not the author
• Any pre-authorization communication has been through regulatory, including the website, investor materials, and anything a rep says in the field
• Launch SOPs and review checklists cite current QMSR provisions rather than the reserved 21 CFR 820.30
• Payments and transfers of value to clinicians are tracked from the first pre-authorization engagement, with a named owner for the reporting obligation

C. Launch day minimum set

• Product pages state the authorized indication in the authorization's own language
• Sales collateral has cleared review, with the review dated and the approver named
• One demand channel is live with a named owner and weekly time committed to it
• Analytics, CRM stages, and the attribution path exist and have been tested with real traffic
• The field is trained, the demo path exists, and objection handling is written

D. The first six months

• A decision date for the first channel is on the calendar, set before launch rather than after
• The volume threshold that makes the result interpretable was defined in advance
• Nothing competing for the same budget has been added before the first channel has a repeatable path

E. The second six months

• Conference shortlist decided, with every contracting and abstract deadline recorded by its actual date
• Commitments staged so the scale of the presence can follow the first half's data
• Named-account list built from observed engagement rather than from a pre-launch guess
• Coverage, coding, and payment has a named owner and milestone dates in the same plan document

F. Standing

• The plan has a review cadence, and the review actually happens when the date slips
• Field-created and distributor-created materials are audited against the approved library
• Claims are re-checked whenever the authorization or the labeling changes

The Five Ways Launches Stall

These are the five failures worth designing against. They are stated as patterns, not as statistics, because Buzzbox Media does not have a measured failure rate to publish and would not publish somebody else's.

1. The plan is built on a date the company does not control. Calendar dates, no relative-offset version, and a fixed commitment or two signed against them. The submission moves, which submissions do, and the plan has to be rebuilt from scratch at exactly the moment the team has least time. Section 1 is the fix and it costs one hour at the start.

2. Day-one collateral enters regulatory review after the authorization instead of before. The clearance arrives and the launch waits several weeks for review, or worse, ships unreviewed because the date was promised to a board. Building the claims matrix and the review chain in the pre-clearance window is the single highest-leverage thing on this page, because it converts review from a bottleneck into a formality.

3. Five channels at once, no attribution, and the wrong one gets cut. The pressure to look busy in the first quarter produces breadth, breadth produces uninterpretable data, and the channel that gets cut is the one whose results are slowest to appear rather than the one that does not work. Organic and account-based work are usually the casualties, and they are usually the ones that would have compounded.

4. Marketing launches and sales cannot sell yet. Untrained field, no demo path, no objection handling, collateral still in review. The conversations marketing generates go nowhere, and the post-mortem blames the channel. Field readiness belongs on the checklist as a gate.

5. Nobody owns the number, or the owner changed at month three. Ownership diffuses, the review cadence quietly stops, and by month six there is no one who can say what the plan was supposed to produce. One name per stage, written in the plan, is a boring fix for the most common failure on the list.

Frequently Asked Questions

How do you plan a medical device product launch? Build the plan backward from the clearance date rather than forward from the calendar. Use the pre-clearance window to build the website, the positioning, the messaging, and the sales tools, while claims about the device wait for the authorization. Launch with four things live: a site that states the authorized indication correctly, reviewed sales collateral, one demand channel you can staff, and a way to tell whether it worked. Spend the first half of year one proving that one channel produces qualified conversations repeatably, then add conference presence and named-account work in the second half. Every date in the plan should be written as an offset from the authorization, not as a calendar date, so the whole plan re-dates itself when the submission moves.

When should medical device launch marketing start? Before the authorization, because the work that takes longest is the work that does not depend on it. Positioning, message architecture, the website build, the claims matrix, and the review chain all take real time and none of them require a clearance to begin. What waits is the promotion of the device itself. The practical test is whether a piece of work would have to be redone if the indication came back narrower than expected. Work that survives a narrower indication can usually start now. Work that would have to be rebuilt should wait for the authorization language.

What can a medical device company do before FDA clearance? This is a question for your regulatory lead about your specific device and pathway, not a question with one general answer. What companies commonly have in flight before an authorization exists is the corporate website, the positioning and message architecture, market and buyer research, the claims matrix, the review chain, sales tool structure, and relationships with clinicians and distributors. What commonly waits is any claim about the device's clinical performance or availability. For an investigational device, 21 CFR 812.7 prohibits promoting or test marketing it before FDA has approved it for commercial distribution and prohibits representing it as safe or effective for the purposes being investigated.

What has to be ready on medical device launch day? Four things, and most launch plans over-build three of them and skip the fourth. A website whose product pages state the authorized indication in the authorization's own language. Sales collateral that has cleared regulatory review, with the review dated and the approver named. One demand channel that a real person is staffed to run every week. And a measurement path that connects a first touch to a qualified conversation, defined before launch rather than reconstructed afterward. A launch missing the fourth one cannot tell you anything about the first three.

How long does a medical device launch take? The marketing arc is usually planned as a twelve-month sequence from the authorization, but the revenue timing is set by the buyer chain rather than by the marketing calendar. A device sold to an individual clinician can convert inside that window. A device that has to clear a hospital value analysis committee, a capital budget cycle, or a reimbursement pathway often cannot, regardless of how well the launch is run. Plan the marketing in twelve months and set the revenue expectation from the buying process you actually face, because holding the plan to a revenue date the buyer chain cannot support is what usually causes a working channel to get cut early.

---

What to do next

1. Rewrite your existing plan's dates as offsets. Take the plan you have, replace every calendar date with an offset from the authorization, and split the result into elastic and fixed commitments. This is an hour of work and it is the highest-value hour in the whole exercise.
2. Start the claims matrix now, empty. Every claim you intend to make in one column, its intended source in the other. Filling it during the pre-clearance window is what makes launch-day review fast.
3. Name one owner per stage. Use the table in section 6, put real names in it, and circulate it. The gaps you find are the plan's actual risks.
4. Pick one demand channel and set its decision date before you launch it. Write down the volume threshold that will make the result interpretable, so the decision is not made on a hunch in month five.
5. Working back from a clearance date? Buzzbox Media works exclusively with medtech companies and healthcare associations, with over 15 years in the category, and builds launch plans anchored to the authorization date rather than to the calendar. Book a 30-minute call.

Related reading: the medical device product launch guide, medical device go-to-market strategy, 510(k) marketing strategy, De Novo and PMA launch marketing, the healthcare PR launch checklist, and AI for medical device product launch. For the claims and review side, see medical device promotional review. For launch support, see medical device marketing or start at Module 5 of the Medical Device Launch Roadmap.

This guide is general information, not legal or regulatory advice. Section 2 describes what companies commonly do before an authorization exists, which is not the same as permission. Consult your regulatory affairs and legal teams before any pre-authorization communication.

This guide is published by Buzzbox Media, a medical device marketing agency in Nashville. We run medical device marketing for medical device companies.

Continue reading

• Medical Device Promotional Review: What a Promo Piece Needs Before It Ships, 14 min read
• FDA Conference Compliance: Booth Rules for Medical Devices, 8 min read
• Medical Conference Exhibitor Guide 2026: Costs and ROI, 18 min read